CEVEC Pharmaceuticals

company

About

CEVEC Pharmaceuticals develops therapeutic proteins and monoclonal antibodies with human glycosylation patterns.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$5.40M
Industries
Biopharma,Biotechnology,Health Care
Founded date
Jan 1, 2003
Number Of Employee
11 - 50
Operating Status
Active

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.

CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$5.40M €10M
CEVEC Pharmaceuticals has raised a total of $5.40M €10M in funding over 2 rounds. Their latest funding was raised on Jul 25, 2011 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 25, 2011 Series Unknown €6M 1 Detail
Feb 2, 2010 Series B $5.40M 1 Detail
Nov 19, 2009 Series A €4M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
CEVEC Pharmaceuticals is funded by 1 investors. ERP Startfonds are the most recent investors.
Investor Name Lead Investor Funding Round
ERP Startfonds Series Unknown